GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » EV-to-FCF

Hikma Pharmaceuticals (LSE:HIK) EV-to-FCF : 12.09 (As of Dec. 11, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hikma Pharmaceuticals's Enterprise Value is £5,095 Mil. Hikma Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was £421 Mil. Therefore, Hikma Pharmaceuticals's EV-to-FCF for today is 12.09.

The historical rank and industry rank for Hikma Pharmaceuticals's EV-to-FCF or its related term are showing as below:

LSE:HIK' s EV-to-FCF Range Over the Past 10 Years
Min: 10.07   Med: 22.19   Max: 68.29
Current: 11.96

During the past 13 years, the highest EV-to-FCF of Hikma Pharmaceuticals was 68.29. The lowest was 10.07. And the median was 22.19.

LSE:HIK's EV-to-FCF is ranked better than
76.31% of 553 companies
in the Drug Manufacturers industry
Industry Median: 25.77 vs LSE:HIK: 11.96

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-11), Hikma Pharmaceuticals's stock price is £19.56. Hikma Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £0.672. Therefore, Hikma Pharmaceuticals's PE Ratio (TTM) for today is 29.11.


Hikma Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Hikma Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals EV-to-FCF Chart

Hikma Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.92 35.00 17.70 14.35 11.22

Hikma Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.70 - 14.35 - 11.22

Competitive Comparison of Hikma Pharmaceuticals's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hikma Pharmaceuticals's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's EV-to-FCF falls into.



Hikma Pharmaceuticals EV-to-FCF Calculation

Hikma Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=5094.692/421.3
=12.09

Hikma Pharmaceuticals's current Enterprise Value is £5,095 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was £421 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hikma Pharmaceuticals  (LSE:HIK) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Hikma Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=19.56/0.672
=29.11

Hikma Pharmaceuticals's share price for today is £19.56.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £0.672.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Hikma Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Hikma Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1 New Burlington Place, London, GBR, W1S 2HR
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Hikma Pharmaceuticals Headlines

No Headlines